Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ILK | Q13418 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | XBP1 | P17861 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2022385 | 0.82 | TSHR (0.44) | TSHRALDH1A1CYP1A2KDM4EHSD17B10 | |
| SCHEMBL691044 | 0.81 | ALDH1A1 (0.47) | TSHRALDH1A1CYP1A2KDM4EHSD17B10 | |
| SCHEMBL3333926 | 0.81 | ALDH1A1 (0.50) | TSHRALDH1A1CYP1A2KDM4EHSD17B10 | |
| SCHEMBL1249727 | 0.81 | TSHR (0.43) | TSHRALDH1A1CYP1A2KDM4EHSD17B10 | |
| SCHEMBL2594859 | 0.80 | NPSR1 (0.45) | ALDH1A1KDM4EHSD17B10HPGDPKM | |
| SCHEMBL18467314 | 0.80 | TSHR (0.43) | TSHRALDH1A1CYP1A2KDM4EHSD17B10 | |
| SCHEMBL1179173 | 0.79 | ALDH1A1 (0.49) | TSHRALDH1A1CYP1A2KDM4EHSD17B10 | |
| SCHEMBL9750587 | 0.79 | ILK (0.43) | TSHRALDH1A1CYP1A2KDM4EHSD17B10 | |
| SCHEMBL1527765 | 0.79 | TSHR (0.42) | TSHRALDH1A1CYP1A2KDM4EHSD17B10 | |
| SCHEMBL3330523 | 0.78 | ALDH1A1 (0.44) | TSHRALDH1A1CYP1A2KDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250002497-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL MYERS SQUIBB CO (US) | 2025-01-02 | — | — | US | disclosed |
| CN-108383858-B | Derivatives of imidazothiadiazoles and imidazopyrazines for the treatment of platelet aggregation | 百时美施贵宝公司 | 2024-09-20 | — | — | CN | disclosed |
| US-12084452-B2 | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-09-10 | — | — | US | disclosed |
| WO-2024102455-A1 | NON-COVALENT INHIBITORS OF CORONAVIRUS MAIN PROTEASE | EMORY UNIVERSITY (US) | 2024-05-16 | — | — | WO | disclosed |
| US-20230242535-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL MYERS SQUIBB CO (US) | 2023-08-03 | — | — | US | disclosed |
| US-20230242535-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL MYERS SQUIBB CO (US) | 2023-08-03 | — | — | US | disclosed |
| US-20230242535-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL MYERS SQUIBB CO (US) | 2023-08-03 | — | — | US | disclosed |
| EP-3632919-B1 | PHARMACEUTICAL COMPOISITIONS COMPRISING IMIDAZOTHIADIAZOLE AND IMIDAZOPYRIDAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL MYERS SQUIBB CO (US) | 2022-10-26 | — | — | EP | disclosed |
| US-10822343-B2 | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-11-03 | — | — | US | disclosed |
| US-10822343-B2 | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-11-03 | — | — | US | disclosed |
| CN-101193891-A | 2-thioethenyl substituted carbapenem derivatives | MEIJI SEIKA KAISHA (JP) | 2008-06-04 | — | — | CN | disclosed |
| US-20080124384-A1 | Heteroaryl Substituted Piperazinyl-Pyridine Analogues | NEUROGEN CORPORATION | 2008-05-29 | — | — | US | disclosed |
| US-20080124384-A1 | Heteroaryl Substituted Piperazinyl-Pyridine Analogues | NEUROGEN CORPORATION | 2008-05-29 | — | — | US | disclosed |
| US-20080085901-A1 | Heteroaryl Substituted Quinolin-4-Ylamine Analogues | NEUROGEN CORPORATION (US) | 2008-04-10 | — | — | US | disclosed |
| US-20080085901-A1 | Heteroaryl Substituted Quinolin-4-Ylamine Analogues | NEUROGEN CORPORATION (US) | 2008-04-10 | — | — | US | disclosed |
| US-20080085901-A1 | Heteroaryl Substituted Quinolin-4-Ylamine Analogues | NEUROGEN CORPORATION (US) | 2008-04-10 | — | — | US | disclosed |
| EP-1870412-A1 | 2-THIOETHENYL CARBAPENEM DERIVATIVE | MEIJI SEIKA KAISHA LTD. (JP) | 2007-12-26 | — | — | EP | disclosed |
| EP-1836203-A2 | HETEROARYL SUBSTITUTED QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2007-09-26 | — | — | EP | disclosed |
| US-20070004700-A1 | 2-Thioethenyl substituted carbapenem derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2007-01-04 | — | — | US | disclosed |
| WO-2006076646-A2 | HETEROARYL SUBSTITUTED QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004700-A1 | 2-Thioethenyl substituted carbapenem derivatives | MTAP, BLVRB, BPGM | TSHR 1341/4885ALDH1A1 1182/4885CYP1A2 1120/4885 |
| US-20230242535-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | F2RL3, F2R, TMPRSS4 | TSHR 128/4885ALDH1A1 2611/4885CYP1A2 393/4885 |
| US-12084452-B2 | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation | F2RL3, F2R, TMPRSS4 | TSHR 128/4885ALDH1A1 2611/4885CYP1A2 393/4885 |
| US-20080085901-A1 | Heteroaryl Substituted Quinolin-4-Ylamine Analogues | PIGS, GPR52, GPR174 | TSHR 194/4885ALDH1A1 1109/4885CYP1A2 535/4885 |
| US-20080124384-A1 | Heteroaryl Substituted Piperazinyl-Pyridine Analogues | PIGO, GPR52, GPR88 | TSHR 90/4885ALDH1A1 1028/4885CYP1A2 421/4885 |
| US-10822343-B2 | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation | F2RL3, TMPRSS4, F2R | TSHR 147/4885ALDH1A1 2559/4885CYP1A2 383/4885 |
| US-20250002497-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | F2RL3, F2R, TMPRSS4 | TSHR 124/4885ALDH1A1 2524/4885CYP1A2 404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.